Using guidance provided by the FDA for tumor collection and transfer on an existing protocol (FDA IND 13630, Duke IRB 6677; PI: Duane A. Mitchell, M.D., Ph.D.), we have received IRB and FDA approval to use identical processes for the transfer of tumor mate rials for the Re -MATCH protocol. To date, we have successfully transferred 3 specimens from outside institutions for RNA amplification. All attempts to amplify RNA sterilely have been successful whether tumor specimens were collected locally or transferred via overnight shipping. Additionally, we have received strong letters of support and commitment from collaborating institutions to open the phase 2 trial as a multi- institutional study. This would greatly facilitate the enrollment of the targeted number of evaluable subjects in a timely manner. Guidelines from the FDA have been obtained on centralized cellular manufacturing for the treatment of subjects at outside institutions. As no study drug is administered during either the Induction phase or the Sal vage chemotherapy phase of the trial, the regimens for both Group A and Group B patients and the mobilization and collection of PBSCs may be administered at UF or other Foundation for the Accreditation of Cellular Therapy (FACT) -accredited medical institutions under the care of a board- certified/board -eligible pediatric oncologist. PBSC products collected and cryopreserved at FACT -accredited institutions shall be shipped in a dry shipper to the UF Stem Cell Laboratory per SOPs prior to Consolidation (Group A) or NMA conditioning with cyclophosphamide and fludarabine (Group B). Dr.